## Page 1 of 2

1020, 432

TRANSAUTTAL STATEMENT CON	Attny. Docket No. 2001B094			
In Re Application of: Lumgair et al.				
U.S. Serial No. Awaited	Filing Date October 30, 2001	Examiner Not Yet Assigned	Group Art Unit Not Yet Assigned	

Address to: **Assistant Commissioner for Patents** Washington, D.C. 20231

## 37 CFR § 1.97(b)

 $\boxtimes$ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

## 37 CFR § 1.97(c)

The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of:

- a Final Action under § 1.113, 1.
- 2. a Notice of Allowance under § 1.311, or
- an action that otherwise closes prosecution in the application, 3.

and is accompanied by either:

П

the fee as set forth in  $\S 1.17(p)$ , or the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

## 37 CFR § 1.97(d)

The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby requests consideration of the Infor 1449, submitted herewith.	mation Disclosure Statement, USPTO form			
☐ Legible copies of the references are enclosed.				
☐ This application is a: ☐ Continuation/ <i>Divisional</i> , ☐ Continuation-in-Part,				
of U.S.S.N Copies of the cited references are not enclosed. References are				
The Commissioner is hereby authorized to charge arthis paper, or credit any overpayment, to Deposit A of this form is enclosed.				
Doc 17,2001 (Date)	Paul T. LaVoie Attorney for Applicants Registration No. 36,861			
	ExxonMobil Chemical Company Law Technology P.O. Box 2149 Baytown, Texas 77522-2149 Phone: 281-834-5080 Fax: 281-834-2911			
CERTIFICATE UNDER 37 C.F.R. §1.8(a)				

I hereby certify that I have a reasonable basis to expect that this correspondence will be deposited with the United States Postal Service as first class mail in an envelope with sufficient postage affixed and addressed to Commissioner of Patents and Trademarks, Washington, DC. 20231, on December 17, 2001.

Mia G. Marron